It also was shown in a small study involving patients with locally advanced breast cancer that tumor levels of nuclear (activated) NF-κB could be used to distinguish between responders and nonresponders to neoadjuvant anthracycline- and/or taxane-based chemotherapy regimens [45]. The gene discussed is NFKB1; the disease is breast carcinoma.